Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilengitide Plus Bevacizumab in Recurrent Glioblastoma
NCT01782976Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2013
- Primary completion
- Jun 2017
- Modality
- Small Molecules, Modified Peptides
01
Overview
A Phase 2 trial of cilengitide in glioblastoma (GBM), sponsored by University of Texas MD Anderson Cancer Center. Planned start Jun 2013; status: withdrawn.
02
Drugs
cilengitide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT01782976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01782976.